These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30623359)

  • 41. Regulatory Frameworks for Gene and Cell Therapies in Japan.
    Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
    Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CellCAN: a unique enabler of regenerative medicine and cell therapy in Canada.
    Roy DC; Alarco AM; Isasi R
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():24-8. PubMed ID: 25457957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDA regulation of allogeneic islets as a biological product.
    Weber DJ
    Cell Biochem Biophys; 2004; 40(3 Suppl):19-22. PubMed ID: 15289639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regenerative Medicine Therapies for Rare Diseases.
    Lapteva L; Vatsan R; Purohit-Sheth T
    Transl Sci Rare Dis; 2018 Dec; 3(3-4):121-132. PubMed ID: 30613470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Navani A; Manchikanti L; Albers SL; Latchaw RE; Sanapati J; Kaye AD; Atluri S; Jordan S; Gupta A; Cedeno D; Vallejo A; Fellows B; Knezevic NN; Pappolla M; Diwan S; Trescot AM; Soin A; Kaye AM; Aydin SM; Calodney AK; Candido KD; Bakshi S; Benyamin RM; Vallejo R; Watanabe A; Beall D; Stitik TP; Foye PM; Helander EM; Hirsch JA
    Pain Physician; 2019 Jan; 22(1S):S1-S74. PubMed ID: 30717500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell therapy worldwide: an incipient revolution.
    Rao M; Mason C; Solomon S
    Regen Med; 2015; 10(2):181-91. PubMed ID: 25835482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achieving reimbursement for regenerative medicine products in the USA.
    Ginty PJ; Singh PB; Smith D; Hourd P; Williams DJ
    Regen Med; 2010 May; 5(3):463-9. PubMed ID: 20455656
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential Therapeutic Strategies of Regenerative Medicine for Renal Failure.
    Mata-Miranda MM; Delgado-Macuil RJ; Rojas-Lopez M; Martinez-Flores R; Vazquez-Zapien GJ
    Curr Stem Cell Res Ther; 2017; 12(5):423-431. PubMed ID: 28322169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Update on Regulation of Regenerative Medicine in Taiwan.
    Chao WY; Chang YT; Tsai YT; Huang MC; Lin YC; Wu MM; Chi JF; Lin CL; Cheng HF; Wu SM
    Adv Exp Med Biol; 2023; 1430():211-219. PubMed ID: 37526850
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acceptance and Access to Gene Editing: Science and Our Obligations to Mankind.
    Fong Y; Hackett PB
    Mol Ther; 2017 Jan; 25(1):1-2. PubMed ID: 28129104
    [No Abstract]   [Full Text] [Related]  

  • 51. Regulation of Cell and Gene Therapy Medicinal Products in Taiwan.
    Lin YC; Wang PY; Tsai SC; Lin CL; Tai HY; Lo CF; Wu SI; Chiang YM; Liu LL
    Adv Exp Med Biol; 2015; 871():181-94. PubMed ID: 26374219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
    Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
    Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Viral vector-mediated transgenic cell therapy in regenerative medicine: safety of the process.
    Liu Y; Wang DA
    Expert Opin Biol Ther; 2015 Apr; 15(4):559-67. PubMed ID: 25528865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell-based therapy approaches: the hope for incurable diseases.
    Buzhor E; Leshansky L; Blumenthal J; Barash H; Warshawsky D; Mazor Y; Shtrichman R
    Regen Med; 2014; 9(5):649-72. PubMed ID: 25372080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Report of the International Regulatory Forum on Human Cell Therapy and Gene Therapy Products.
    Hayakawa T; Harris I; Joung J; Kanai N; Kawamata S; Kellathur S; Koga J; Lin YC; Maruyama Y; McBlane J; Nishimura T; Renner M; Ridgway A; Salmikangas P; Sakamoto N; Sato D; Sato Y; Toda Y; Umezawa A; Werner M; Wicks S
    Biologicals; 2016 Sep; 44(5):467-79. PubMed ID: 27461129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging Translation of Regenerative Therapies.
    Allickson JG
    Clin Pharmacol Ther; 2017 Jan; 101(1):28-30. PubMed ID: 27806427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination products neglected by FDA device evaluation.
    Waters H
    Nat Med; 2011 Sep; 17(9):1024. PubMed ID: 21900899
    [No Abstract]   [Full Text] [Related]  

  • 58. Awareness of the role of science in the FDA regulatory submission process: a survey of the TERMIS-Americas membership.
    Johnson PC; Bertram TA; Carty NR; Hellman KB; Tawil BJ; Van Dyke M
    Tissue Eng Part A; 2014 Jun; 20(11-12):1565-82. PubMed ID: 24665855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Scope and limitations of gene therapy.
    Weatherall DJ
    Br Med Bull; 1995 Jan; 51(1):1-11. PubMed ID: 7767636
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cell Therapy Regulatory Toolkit: an online regulatory resource.
    Culme-Seymour EJ; Davies JL; Hitchcock J; Mason J; Carpenter MK; Mason C
    Regen Med; 2015; 10(5):531-4. PubMed ID: 26237697
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.